Search Results for keywords:"pharmaceutical companies"

Search Results: keywords:"pharmaceutical companies"

H. R. 9021 — To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for prescription drugs.
July 11, 2024
Status:Introduced in House
Congress:118
Words:519
H. R. 9021 proposes an amendment to the Internal Revenue Code of 1986 that would prevent companies from deducting expenses related to direct-to-consumer advertising of prescription drugs from their taxes. This means that businesses will no longer receive a tax break for money...
Simple Explanation
H. R. 9021 is a proposed rule that would stop drug companies from getting a tax discount for showing ads on TV or the internet to sell their medicines. This means they might spend less money on commercials, and people might see fewer ads about medicines.
H. R. 6956 — To amend title XIX of the Social Security Act to prohibit the Secretary of Health and Human Services from treating any Medicaid-related funds recovered from one or more pharmaceutical companies or drug distributors with respect to opioid litigation as an overpayment under such title, and for other purposes.
January 11, 2024
Status:Introduced in House
Congress:118
Words:705
H.R. 6956, also known as the "Opioid Settlement Accountability Act," proposes an amendment to the Social Security Act. This bill aims to ensure that Medicaid-related funds recovered from pharmaceutical companies or drug distributors through opioid litigation are not...
Simple Explanation
The bill says that if money is paid by drug companies because they made or sold too many pain pills, the government should use that money to help people feel better and stop taking too many pills, instead of just putting it back in their big money pool.
H. R. 9616 — To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes.
September 17, 2024
Status:Introduced in House
Congress:118
Words:621
The bill H. R. 9616 aims to amend the Federal Food, Drug, and Cosmetic Act to allow quicker approval of drugs when new safety information is added to their labeling. It ensures that a drug won't be considered ineligible for approval if its labeling omits safety details that...
Simple Explanation
The bill wants to make it faster to approve new medicines by adding important safety information to their labels. It also makes sure these medicines have the right safety details on their labels, but doesn't change any special rights companies have over their medicine information.

Showing 1 to 3 of 3 results